Circulating prostaglandin $ E_{2} $: a novel potential prognostic biomarker in patients with hepatocellular carcinoma
Abstract We aimed to explore the activation of monoacylglycerol lipase (MAGL)/cyclooxygenase-2 (COX-2)/prostaglandin $ E_{2} $ (PGE2) axis in hepatocellular carcinoma (HCC), evaluating circulating PGE2 as prognostic biomarker in HCC patients. PGE2 levels were measured in blood samples from 24 cirrhotics, and 34 HCC patients were consecutively collected between January 2016 and December 2017. In a subgroup of patients, tissue expression of MAGL mRNA and immunohistochemistry for MAGL and COX-2 were obtained. Despite tumor tissues showing overexpression of MAGL mRNA and higher levels of both MAGL and COX-2 at immunohistochemistry, PGE2 levels were not significantly different in HCC and cirrhotics. HCC patients with circulating PGE2 levels > 14 pg/mL had a significantly shorter overall survival (19.4 vs. 49.9 months; p = 0.03), the finding being confirmed by the multivariate analysis (HR 3.37 [95% CI 1.00–11.60]; p = 0.05). The MAGL/COX-2/PGE2 axis is activated in HCC, and circulating PGE2 proved to be a potential prognostic biomarker..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical and experimental medicine - 21(2021), 4 vom: 25. März, Seite 675-682 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pelizzaro, Filippo [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Cyclooxygenase-2 |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 |
|---|
| doi: |
10.1007/s10238-021-00705-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR045268215 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR045268215 | ||
| 003 | DE-627 | ||
| 005 | 20230519160159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211012s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10238-021-00705-z |2 doi | |
| 035 | |a (DE-627)SPR045268215 | ||
| 035 | |a (SPR)s10238-021-00705-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.60 |2 bkl | ||
| 100 | 1 | |a Pelizzaro, Filippo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Circulating prostaglandin $ E_{2} $: a novel potential prognostic biomarker in patients with hepatocellular carcinoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 | ||
| 520 | |a Abstract We aimed to explore the activation of monoacylglycerol lipase (MAGL)/cyclooxygenase-2 (COX-2)/prostaglandin $ E_{2} $ (PGE2) axis in hepatocellular carcinoma (HCC), evaluating circulating PGE2 as prognostic biomarker in HCC patients. PGE2 levels were measured in blood samples from 24 cirrhotics, and 34 HCC patients were consecutively collected between January 2016 and December 2017. In a subgroup of patients, tissue expression of MAGL mRNA and immunohistochemistry for MAGL and COX-2 were obtained. Despite tumor tissues showing overexpression of MAGL mRNA and higher levels of both MAGL and COX-2 at immunohistochemistry, PGE2 levels were not significantly different in HCC and cirrhotics. HCC patients with circulating PGE2 levels > 14 pg/mL had a significantly shorter overall survival (19.4 vs. 49.9 months; p = 0.03), the finding being confirmed by the multivariate analysis (HR 3.37 [95% CI 1.00–11.60]; p = 0.05). The MAGL/COX-2/PGE2 axis is activated in HCC, and circulating PGE2 proved to be a potential prognostic biomarker. | ||
| 650 | 4 | |a Hepatocellular carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prostaglandin E |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Monoacylglycerol lipase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cyclooxygenase-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Survival |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kitenge, Maria Piera |e verfasserin |4 aut | |
| 700 | 1 | |a Cardin, Romilda |e verfasserin |4 aut | |
| 700 | 1 | |a Ponzoni, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Cillo, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Vitale, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Businello, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Munari, Giada |e verfasserin |4 aut | |
| 700 | 1 | |a Fassan, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Farinati, Fabio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental medicine |d Milano : Springer, 2001 |g 21(2021), 4 vom: 25. März, Seite 675-682 |w (DE-627)SPR009227598 |w (DE-600)2054398-0 |x 1591-9528 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:4 |g day:25 |g month:03 |g pages:675-682 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10238-021-00705-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.60 |q ASE |
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 4 |b 25 |c 03 |h 675-682 | ||